What is the real market size of the healthcare AI market?

The healthcare AI market reached approximately 26 to 29 billion dollars in 2024.

It is growing at 36 to 40 percent annually, making it one of the fastest-expanding enterprise software categories.

Healthcare has transformed from a digital laggard to an AI adoption leader, deploying AI at 2.2 times the rate of the broader economy.

And if you want to better understand this new industry, you can download our pitch covering the healthcare AI.

How do we define the healthcare AI?

We define the healthcare AI market as AI software and models used by healthcare providers, payers, life sciences companies, medtech firms, and public health bodies to improve clinical care, operations, and research.

We include clinical decision support, diagnostic and monitoring tools, hospital and clinic workflow and revenue cycle automation, payer analytics and claims tools, as well as AI used in pharma and biotech R&D, clinical trials, and connected medical devices.

We exclude general-purpose AI infrastructure, pure consumer wellness and fitness apps, and horizontal enterprise tools that are not purpose-built or primarily sold for healthcare use.

We also use this definition when we make and update our our pitch covering everything there is to know about the healthcare AI

What is the size of the healthcare AI in 2026?

What results can we find on the internet?

As you probably know already, many firms regularly publish (sometimes conflicting) estimates of the healthcare AI size, using different definitions, scopes, and years.

We have consolidated their results here. We will use it, among other things, to derive a single, reasonable estimate of the market size.

Research Firm	Market Size	Year	Market Definition
Fortune Business Insights	$29.01B	2024	Comprehensive scope including diagnostics, imaging, administrative automation, patient monitoring, drug discovery, and robotic surgery. Broader than our definition as it includes robotic surgery hardware.
Grand View Research	$26.57B	2024	Covers robot-assisted surgery, clinical trials optimization, fraud detection, and drug discovery AI. Aligns closely with our definition though includes some hardware components.
Precedence Research	$26.69B	2024	Focuses on software solutions for medical imaging, drug discovery, and provider-payer operations. Matches our definition very closely.
Mordor Intelligence	~$32B	2024	Includes machine learning applications, diagnostics software, and healthcare provider tools. Somewhat broader than our scope.
Towards Healthcare	$27.59B	2024	Covers software, robot-assisted surgery, machine learning for healthcare companies. Slightly broader than our definition.
Market.us	$26.8B	2024	Includes hardware at 45 percent, machine learning at 46 percent, robot-assisted surgery at 25 percent. Broader scope including significant hardware components.
MarketsandMarkets	$14.92B	2024	Narrower definition focusing on diagnosis, genomics, and precision medicine software. More conservative and limited than our scope.
Future Market Insights	$14.55B	2024	Emphasizes robot-assisted surgery at 30 percent and healthcare providers at 60 percent. Narrower focus than our definition.
Allied Market Research	~$50B+	2024	Very broad scope with aggressive projections including adjacent digital health categories. Significantly broader than our definition.
Global Market Insights	$18.7B	2023	Emphasizes medical imaging and diagnostics AI applications. More focused than our comprehensive definition.
Data Bridge Market Research	$22.23B	2024	Covers medical imaging, diagnostics, and personalized treatment tools. Aligns reasonably well with our definition.

What can we conclude, then?

The median estimate across research firms clusters around 26 to 27 billion dollars for 2024, which provides a strong baseline for the healthcare AI market.

The approximately two-times difference between high estimates around 29 billion dollars and low estimates around 15 billion dollars primarily reflects whether sources include pharma R&D AI, connected medical devices, and payer analytics within their scope.

Given our comprehensive definition that includes clinical decision support, diagnostics, workflow automation, revenue cycle management, and life sciences R&D, we estimate the healthcare AI market at approximately 28 billion dollars in 2024, and this is our first estimate that we will refine further.

What if we try to make our own estimate?

We don't have to rely only on external analyses to estimate market size.

We will try to build a first-principles, bottom-up calculation, then run a few sanity checks to see whether we can reliably estimate the size of the healthcare AI.

Useful data about the healthcare AI

Here is some useful and reliable data we have collected, they will help us estimate the size of the healthcare AI:

• The US has 6,120 hospitals including 5,129 community hospitals with 784,112 staffed beds as of 2022 (AHA Annual Survey 2024)
• There are conservatively 150,000 plus hospitals globally when all countries are included based on regional data (AHA Annual Survey 2024)
• Average US hospital IT expense is 6.12 million dollars with small hospitals at approximately 1.2 million and large hospitals exceeding 36 million (HealthIT.gov)
• Healthcare AI as share of IT spending grew from 5.5 percent in 2022 to 10.5 percent plus in 2024, doubling in two years (HealthIT.gov)
• 71 percent of US hospitals use predictive AI in 2024, up from 66 percent in 2023 (HealthIT.gov)
• 31.5 percent of US hospitals use EHR-integrated generative AI in 2024 with 24.7 percent planning adoption within one year (HealthIT.gov)
• 66 percent of US physicians use AI tools in 2024, up 78 percent from 38 percent in 2023 (HealthIT.gov)
• The AI in revenue cycle management market reached 20.63 billion dollars in 2024 (Grand View Research)
• The AI in drug discovery market reached 1.72 to 1.86 billion dollars in 2024 (MarketsandMarkets)
• The FDA has authorized 1,016 AI and ML medical devices as of December 2024 with 736 unique devices (Nature Digital Medicine)
• Healthcare AI-specific VC spending reached 500 million dollars in 2024 and 1.4 billion dollars in 2025 (Menlo Ventures)
• The average ROI for AI in healthcare is 3.20 dollars per dollar invested with 14 months time to ROI (Menlo Ventures)

Method and calculation to get the size of the healthcare AI

Let's start with US hospitals as the foundation. The 6,120 US hospitals spend an average of 6.12 million dollars on IT annually.

This gives us approximately 37.5 billion dollars in total US hospital IT spending.

Healthcare AI now represents 10.5 percent of IT spending in 2024, up from 5.5 percent in 2022. This doubling reflects the rapid adoption we see across the industry.

Applying 10.5 percent to the 37.5 billion dollars in US hospital IT spending yields approximately 3.9 billion dollars for US hospital AI spending.

But hospitals are just one segment. We also need to account for physician practices, payers, pharma and biotech companies, and medtech firms.

Physician practices represent a significant market with 66 percent of US physicians now using AI tools.

The revenue cycle management AI market alone is 20.63 billion dollars globally. This includes both provider and payer RCM systems.

Drug discovery AI adds another 1.72 to 1.86 billion dollars to the total.

If we consider that US hospitals at 3.9 billion dollars represent approximately 30 to 35 percent of the US healthcare AI market, the total US market would be 11 to 13 billion dollars.

The US typically represents 45 to 50 percent of the global healthcare AI market based on research firm data.

This calculation suggests a global healthcare AI market of 22 to 26 billion dollars. We need to add the RCM market of 20.63 billion dollars, but this may overlap with our hospital spending calculations.

After adjusting for overlaps and ensuring we capture all segments, our bottom-up estimate points to approximately 27 to 30 billion dollars for 2024.

Sanity checks

Our estimate of 27 to 30 billion dollars aligns well with the median of published research at 26 to 27 billion dollars. This consistency across methodologies strengthens confidence in the range.

The global healthcare IT market is 313 to 760 billion dollars depending on scope. Our healthcare AI estimate of 27 to 30 billion dollars represents 4 to 10 percent of healthcare IT spending.

This percentage matches the observed 10.5 percent AI penetration rate in hospital IT budgets.

With 71 percent of US hospitals using predictive AI and 31.5 percent using generative AI, we should see significant spending. The adoption rates support a market of this size.

The 1,016 FDA-authorized AI devices also indicate a mature and substantial market.

Healthcare AI VC funding reached 3.95 billion dollars in H1 2025 alone, representing 62 percent of all digital health funding. This level of investment activity is consistent with a 27 to 30 billion dollar market.

Eight healthcare AI unicorns exist with valuations totaling over 20 billion dollars combined.

What's our final guess then?

Based on our analysis of published estimates, bottom-up calculations, and validation checks, we estimate the healthcare AI market at approximately 29 billion dollars in 2026.

This represents growth from the 26 to 28 billion dollar range in 2024.

The healthcare AI market in 2026 is comparable in size to the global cybersecurity software market at approximately 30 billion dollars. It is also similar to the customer relationship management software market at around 32 billion dollars.

These comparisons make intuitive sense. Healthcare AI is transforming a 4 trillion dollar US healthcare system and an 8 trillion dollar global healthcare economy.

The market size reflects early-stage penetration with massive room for growth.

The 29 billion dollar healthcare AI market in 2026 also aligns with infrastructure metrics. With 150,000 plus hospitals globally and growing physician adoption at 66 percent, the spending levels support this market size.

Is the healthcare AI mature, competitive, fragmented ?

The maturity score of the healthcare AI in 2026 is 35/100

The healthcare AI market in 2026 shows early-stage characteristics despite rapid recent growth. Only 22 percent of healthcare organizations have implemented domain-specific AI tools, though this is seven times higher than 2024.

Regulatory frameworks are still developing with the FDA finalizing Predetermined Change Control Plans guidance only in December 2024. No AI-first drug has completed the approval process yet, though 67 AI-discovered molecules are in clinical trials.

These indicators point to a market still in its formative years.

However, certain segments show higher maturity. Ambient clinical documentation achieved 100 percent adoption activity across surveyed health systems.

Radiology AI has 76 to 80 percent of all FDA-approved devices concentrated in this area, indicating relative maturity in medical imaging.

The competitive score of the healthcare AI in 2026 is 75/100

The healthcare AI market in 2026 is highly competitive with eight healthcare AI unicorns and hundreds of funded startups. No single company holds more than 15 percent overall market share.

Competition is intense in ambient clinical documentation where Microsoft's Nuance with 33 percent market share faces strong challenges from Abridge at 30 percent and Ambience at 13 percent. AI-native startups captured approximately 70 percent of new ambient scribe market share despite incumbent advantages.

85 percent of generative AI spending flows to startups rather than established players.

However, platform players like Epic, Oracle Health, and athenahealth are building AI directly into EHR systems. 90 percent AI usage occurs among Epic EHR users versus approximately 50 percent for other systems.

This creates competitive pressure as customers prefer buying from incumbent EHRs.

The fragmentation score of the healthcare AI in 2026 is 85/100

The healthcare AI market in 2026 is highly fragmented with 1,016 FDA-authorized AI and ML medical devices from 736 unique products. Multiple distinct subcategories each have different leaders with no dominant player across segments.

The market structure reflects specialization by clinical area, use case, and customer segment. Radiology AI, revenue cycle management, drug discovery, clinical trials, and ambient documentation each have separate competitive dynamics.

Eight healthcare AI unicorns operate in different segments without significant overlap.

Consolidation is beginning with 107 M&A deals in H1 2025, nearly double the 118 deals in all of 2024. Private equity firms are executing roll-up strategies combining AI-native startups with legacy players.

Despite this activity, the healthcare AI market in 2026 remains one of the most fragmented enterprise software categories.

How much bigger will the healthcare AI be in 10 years?

What are the different forecasts for the growth rate of healthcare AI?

One more time, let's check what other market research firms have to say.

Research Firm	Annual Growth Rate	Until Year	Comments
Mordor Intelligence	37.6%	2030	Includes ML, diagnostics, and healthcare providers which matches our definition closely. We can use this rate with confidence. Forecast period is 2025 to 2030.
MarketsandMarkets	38.6%	2030	Narrower definition focusing on diagnosis and genomics, lower base leads to higher growth rate. We should adjust downward slightly. Forecast period is 2025 to 2030.
Grand View Research	38.81%	2033	Comprehensive scope including robot-assisted surgery and clinical trials, aligns well with our definition. Reliable for our estimate. Longer forecast period extends to 2033.
Precedence Research	36.83%	2034	Software solutions for providers and payers, very close to our scope. Strong alignment makes this highly relevant. Extended forecast to 2034.
Fortune Business Insights	44.0%	2032	Broad scope including robotic surgery hardware inflates growth rate. We should weight this lower. Forecast period is 2025 to 2032.
Allied Market Research	38.1%	2030	Broad scope with aggressive projections including adjacent categories. May overstate growth. Forecast from 2021 to 2030.
Research Nester	34.5%	2035	Conservative estimate over very long period suggests steady but slower growth. Useful for long-term projections. Forecast extends to 2035.
Market Research Future	26.2%	2035	Narrower definition of traditional clinical AI applications results in lower growth. Likely underestimates based on current trends. Forecast is 2025 to 2035.
Emergen Research	37.2%	2032	ML and NLP focus aligns with software emphasis in our definition. Reliable mid-range estimate. Forecast period is 2023 to 2032.
Global Market Insights	37.1%	2032	Medical imaging and diagnostics emphasis represents large segment of our market. Good alignment for our estimate. Forecast is 2024 to 2032.
Towards Healthcare	37.66%	2034	Includes software and ML for healthcare companies, matches our definition. Strong consensus alignment. Forecast period is 2025 to 2034.
Data Bridge Market Research	51.87%	2032	Outlier high estimate may include adjacent digital health categories beyond our scope. Should be weighted lower. Forecast is 2025 to 2032.

What can we conclude about the growth rate of the healthcare AI?

Eight of twelve research firms cluster in the 36 to 40 percent CAGR range, providing strong consensus for the healthcare AI growth rate. The median across all sources is approximately 37.5 percent annually.

The outlier low estimate at 26.2 percent from Market Research Future uses a narrower definition focused on traditional clinical applications. The outlier high at 51.87 percent from Data Bridge likely includes adjacent digital health categories.

We can exclude these extremes from our central estimate.

Given our comprehensive definition that includes clinical AI, administrative automation, and life sciences R&D, a growth rate of 37 to 38 percent CAGR through 2030 is appropriate. This aligns with the strong consensus cluster.

After 2030, growth rates typically moderate as markets mature, so we estimate 30 to 32 percent CAGR from 2030 to 2036.

With a 37 percent CAGR from our 2026 base of 29 billion dollars, the healthcare AI market would reach approximately 165 billion dollars by 2030. This represents a 5.7 times multiple over four years.

This projection aligns with the consensus range of 150 to 250 billion dollars by 2030 from multiple research firms.

Extending to 2036 with 37 percent CAGR through 2030 and then 31 percent CAGR from 2030 to 2036, the healthcare AI market would reach approximately 580 billion dollars. This represents a 20 times multiple over ten years.

This ten-year projection fits within the 500 to 650 billion dollar range that research firms project for 2034 to 2035.

For comparison, the cloud computing market grew at approximately 25 percent CAGR and the cybersecurity market at 12 percent CAGR over similar periods. The healthcare AI growth rate of 37 percent exceeds both.

This reflects healthcare transforming from a digital laggard to an AI adoption leader at 2.2 times the rate of the broader economy.

And if you're curious about what's happening in this (really interesting) market, we publish a quarterly update on the activity in the healthcare AI here. We also have a monthly update here.

What is the projected CAGR for the healthcare AI?

At New Market Pitch, we like it when the information is clear and easy to digest, as you will see in the pitch about the healthcare AI. That's also why we have made this clear summary table.

Year	Worst Case (28% annual growth rate)	Realistic (37% annual growth rate)	Best Case (45% annual growth rate)
2027	$37.1B	$39.7B	$42.1B
2028	$47.5B	$54.4B	$61.0B
2029	$60.8B	$74.5B	$88.5B
2030	$77.8B	$102.1B	$128.3B
2031	$99.6B	$139.9B	$186.0B
2032	$127.5B	$191.7B	$269.7B
2033	$163.2B	$262.6B	$391.1B
2034	$208.9B	$359.8B	$567.1B
2035	$267.4B	$492.9B	$822.3B
2036	$342.3B	$675.3B	$1,192.3B

What would it take for the healthcare AI to be worth $700 billion?

Reaching $700 billion by 2036 would require adoption rates to accelerate beyond current projections. Today, 71% of US hospitals use predictive AI and 31.5% use generative AI—this would need to reach 95%+ across hospitals, physician practices, payers, and life sciences companies.

Clinical decision support AI must overcome significant barriers. Its current maturity rate is just 6.8% compared to 53% for documentation. Regulatory frameworks, reimbursement codes, and liability frameworks would all need faster resolution.

Pharma and biotech AI requires breakthrough validation. No AI-first drug has completed approval yet, though 67 molecules are in trials. Multiple AI-discovered drugs reaching market by 2030 would accelerate pharma AI spending from $3 billion in 2025 to the projected $25 billion by 2030.

International expansion must exceed current trajectories. Asia-Pacific's 42.5–50.2% CAGR is promising, but China (35.1% of the region) and India would need major healthcare AI infrastructure investments.

Payer AI adoption must match provider levels. Administrative AI currently captures 60% of investment, but full integration across claims processing, prior authorization, fraud detection, and medical necessity determinations would unlock major spending.

Ambient clinical documentation must move beyond adoption to integration depth—shifting from pilots to full deployment across all clinical encounters, driving per-installation spending from tens of thousands to hundreds of thousands of dollars.

Revenue cycle management AI ($20.63 billion in 2024) would need to exceed its projected 24.2% CAGR, reaching $150 billion+ by 2036. This requires near-complete automation of claims, coding, billing, and collections.

Where is the money in the healthcare AI?

What are the categories and how much do they generate?

Revenue cycle management AI dominates the healthcare AI market in 2026 with approximately 21 to 22 billion dollars, representing 72 to 76 percent of total spending. This includes claims processing, coding, billing, and collections automation.

The concentration reflects healthcare organizations prioritizing ROI-positive administrative applications over higher-risk clinical AI.

Ambient clinical documentation captures 27 percent of AI investment and 42 percent of deal volume, generating approximately 3 to 4 billion dollars in revenue for 2026. Microsoft's Nuance DAX, Abridge, and Ambience lead this segment.

The 100 percent adoption activity rate across surveyed health systems drives rapid growth.

Medical imaging and diagnostics AI generates approximately 1.3 to 2 billion dollars in 2026, representing 4 to 7 percent of the healthcare AI market. Radiology AI accounts for 76 to 80 percent of FDA-approved devices.

However, reimbursement challenges limit revenue despite clinical validation.

Drug discovery and pharma R&D AI produces approximately 1.8 to 2 billion dollars in 2026, roughly 6 to 7 percent of the healthcare AI market. The 67 AI-discovered molecules in clinical trials indicate growing adoption.

Pharma companies investing at 95 percent penetration supports continued expansion.

Clinical trials AI, clinical decision support, patient engagement, and remote monitoring collectively generate approximately 1 to 2 billion dollars, representing the remaining 3 to 7 percent. These categories have lower maturity rates.

Clinical decision support at 6.8 percent maturity and clinical trials at 11 percent full implementation explain limited revenue generation.

Finally, if you really want to understand where is the money, you can check our ranking of the most funded startups in the healthcare AI market as well as our list of the most valued startups.

How will it evolve?

By 2030, revenue cycle management AI will decline to 50 to 55 percent of the healthcare AI market as clinical AI matures. RCM will grow to 50 to 60 billion dollars but represents a smaller share.

Administrative AI approaching saturation allows clinical applications to capture incremental spending.

Ambient clinical documentation will maintain 25 to 30 percent of the healthcare AI market through 2030, reaching 25 to 35 billion dollars. Universal deployment across all clinical encounters drives continued growth.

Integration depth rather than adoption breadth becomes the revenue driver.

Medical imaging and diagnostics AI will grow to 10 to 12 percent of the healthcare AI market by 2030, generating 10 to 15 billion dollars. CMS reimbursement expansion and FDA's streamlined PCCP guidance accelerate clinical AI adoption.

Cardiovascular and neurology AI will gain share beyond radiology's current 76 to 80 percent concentration.

Drug discovery and clinical trials AI will reach 12 to 15 percent of the healthcare AI market by 2030, producing 12 to 18 billion dollars in revenue. AI-first drugs completing approval by 2028 to 2029 validate the approach.

Pharma AI spending accelerating from 3 billion dollars in 2025 toward 25 billion dollars by 2030 drives this expansion.

By 2036, the revenue distribution shifts further toward clinical applications. RCM stabilizes at 35 to 40 percent while clinical decision support, diagnostics, and pharma R&D collectively reach 40 to 45 percent of a 580 to 700 billion dollar healthcare AI market.

Ambient documentation maintains 20 to 25 percent as mature infrastructure supporting clinical workflows.

Where to spend your energy as an investor or a builder in the healthcare AI then?

For investors seeking near-term returns, ambient clinical documentation offers the clearest opportunity with 100 percent adoption activity and 53 percent reporting high success. Companies like Abridge at 2.75 billion dollar valuation demonstrate significant value creation potential.

The category shows product-market fit with average 14-month ROI.

Revenue cycle management AI provides defensive positioning with 20.63 billion dollars current market size and established reimbursement models. However, the segment's 50 to 55 percent projected market share decline by 2030 suggests limited expansion multiples.

Private equity roll-up strategies combining AI-native startups with legacy RCM players represent the main value creation path.

Drug discovery and clinical trials AI offer highest long-term upside with 12 to 15 percent projected market share by 2030 and 95 percent pharma company adoption. Xaira Therapeutics raising 1 billion dollars at launch demonstrates investor appetite.

However, longer time horizons of 5 to 10 years for AI-first drug approvals require patient capital.

Clinical decision support AI remains nascent at 6.8 percent maturity rate but represents massive untapped potential. Regulatory clarity from FDA's PCCP guidance and CMS guardrails finalized in 2024 reduce compliance risk.

Builders focusing on specific clinical workflows with clear ROI metrics can capture first-mover advantages before the segment reaches 10 to 12 percent market share by 2030.

Geographic expansion into Asia-Pacific growing at 42.5 to 50.2 percent CAGR offers growth arbitrage. China at 35.1 percent of Asia-Pacific market and government strategic priorities create favorable conditions.

However, regulatory complexity and localization requirements demand operational expertise beyond North American market experience.

And if you're curious about where investors are putting their money right now, we publish a quarterly update on the fundraising activity in the healthcare AI here. We also analyze long-term funding trends in the healthcare AI here.

What is the geographical revenue breakdown for the healthcare AI?

North America

North America holds 45 to 58.9 percent of the healthcare AI market in 2026, generating approximately 13 to 17 billion dollars. The United States dominates at 31 to 35 percent of global market with advanced healthcare infrastructure and 882 FDA AI device clearances.

Healthcare AI VC funding reached 17.2 billion dollars in 2024 with 58 percent flowing to AI solutions.

By 2030, North America's market share will decline slightly to 42 to 48 percent as Asia-Pacific accelerates. However, absolute revenue will grow to 43 to 50 billion dollars driven by universal provider adoption.

71 percent of hospitals already using predictive AI will reach 95 percent plus penetration.

By 2036, North America stabilizes at 38 to 42 percent of the global healthcare AI market, generating 220 to 280 billion dollars. Market share decline reflects faster international growth rather than domestic weakness.

The US maintains technology leadership through continued innovation from eight healthcare AI unicorns and robust venture funding.

Canada represents 8 to 12 percent of North American healthcare AI spending with government healthcare systems driving adoption. Provincial health authorities implementing AI across standardized infrastructure accelerates deployment.

Europe

Europe captures 25 to 28 percent of the healthcare AI market in 2026, generating approximately 7 to 8 billion dollars. The United Kingdom leads European adoption with NHS active deployment programs.

Germany shows strength in pharma AI given concentration of pharmaceutical and biotech companies.

By 2030, Europe maintains 24 to 27 percent market share reaching 24 to 28 billion dollars. GDPR compliance requirements initially slowed adoption but now provide competitive advantage.

Stricter data privacy frameworks attract healthcare organizations concerned about patient data security.

By 2036, Europe holds 22 to 25 percent of the healthcare AI market generating 128 to 170 billion dollars. The region benefits from universal healthcare systems enabling standardized AI deployment.

However, fragmented procurement across countries limits economies of scale compared to US market concentration.

France, Germany, UK, and Nordic countries collectively represent 70 to 75 percent of European healthcare AI spending. Eastern European markets remain underdeveloped due to lower healthcare IT infrastructure investment.

Asia-Pacific

Asia-Pacific holds 18 to 20 percent of the healthcare AI market in 2026, generating approximately 5 to 6 billion dollars. The region is the fastest growing at 42.5 to 50.2 percent CAGR.

China dominates at 35.1 percent of Asia-Pacific with government strategic priorities driving healthcare AI infrastructure investment.

By 2030, Asia-Pacific will reach 26 to 30 percent of global healthcare AI market producing 26 to 35 billion dollars. China's Baidu Health partnerships and 60 percent plus share of global population create massive addressable market.

India and Southeast Asia contribute growing share as healthcare infrastructure modernizes.

By 2036, Asia-Pacific captures 32 to 38 percent of the healthcare AI market generating 185 to 260 billion dollars. The region will rival or exceed North America in absolute spending.

Demographic advantages including aging populations in Japan and China plus middle class expansion in India drive healthcare AI investment.

Japan maintains highest hospital density in OECD at 8,156 hospitals creating strong institutional demand. Australia and New Zealand represent high-value markets with advanced healthcare systems similar to North America.

Latin America

Latin America represents 6 to 7 percent of the healthcare AI market in 2026, generating approximately 1.7 to 2 billion dollars. Brazil and Mexico are key markets with large populations and growing healthcare systems.

However, lower healthcare IT spending per capita limits market size.

By 2030, Latin America grows to 7 to 8 percent market share reaching 7 to 9 billion dollars. Government initiatives to modernize healthcare infrastructure drive AI adoption.

Telemedicine expansion during COVID accelerated digital health readiness creating foundation for AI deployment.

By 2036, Latin America maintains 7 to 9 percent of the healthcare AI market producing 40 to 60 billion dollars. Economic development and healthcare system maturation support steady growth.

However, the region continues lagging North America and Asia-Pacific in per capita AI spending.

Middle East and Africa

Middle East and Africa holds 4 to 5 percent of the healthcare AI market in 2026, generating approximately 1.2 to 1.5 billion dollars. Gulf Cooperation Council countries lead with significant government investment in healthcare infrastructure.

Sub-Saharan Africa remains underdeveloped but mobile health adoption creates leapfrog opportunities.

By 2030, Middle East and Africa grows to 5 to 6 percent market share reaching 5 to 7 billion dollars. UAE and Saudi Arabia Vision 2030 initiatives include substantial healthcare AI components.

South Africa represents largest sub-Saharan market with established private healthcare sector.

By 2036, Middle East and Africa reaches 6 to 7 percent of the healthcare AI market generating 35 to 48 billion dollars. Oil-producing nations diversifying economies prioritize healthcare technology investments.

However, political instability and limited healthcare infrastructure in many African nations constrain broader regional growth.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.